ClinicalLupus Patients Continue Seeking Experimental CAR-T Therapies Despite Trial...

Lupus Patients Continue Seeking Experimental CAR-T Therapies Despite Trial Deaths

-

Patients with systemic lupus erythematosus (SLE) are continuing to seek access to experimental CAR-T cell therapies despite four reported deaths in clinical trials investigating the treatment for autoimmune diseases. Although the trials remain halted and details surrounding the deaths have not been fully disclosed, doctors treating lupus patients say interest in the experimental approach remains high.

“I have patients that are literally waiting to get in,” said Dr. Anca Askanase, chief of rheumatology at the Hospital for Special Surgery in New York, who has enrolled patients in Bristol Myers Squibb’s CAR-T trials.

SLE is the most common and severe form of lupus. The condition causes agonizing joint pain and increases the risk of stroke, heart attack, and kidney disease. Existing treatment options include steroids, immunosuppressants and targeted biologics, but these medications do not always control the disease. An estimated 10% to 15% of people with lupus die prematurely.

Patients Turn to CAR-T After Existing Treatments Fail

Brittan Kopittke, 27, who works with the University of North Carolina counselling patients considering CAR-T treatment, was diagnosed with lupus at 22. The disease initially appeared as a rash on her chest before progressing to severe joint pain, mouth sores and crushing fatigue.

Treatment with steroids and hydroxychloroquine failed to control her condition. Despite trying several medications, her disease continued to affect her kidneys, heart and lungs. Kopittke said she had reached the end of the line with treatments before enrolling in a CAR-T clinical trial at UNC-Chapel Hill in June 2024.

The personalized immunotherapy involves collecting a patient’s T cells, genetically modifying them to attack harmful immune cells, and returning them to the body. The treatment has been successfully used for blood cancers and is now being investigated for autoimmune conditions.

Kopittke experienced cytokine release syndrome, which causes systemic inflammation, and a severe neurological complication known as ICANS. The latter left her unresponsive for three days. However, she has now been in remission for approximately two years.

Although she discusses the potential dangers with patients considering the treatment, Kopittke said she would undergo the procedure again.

Trial Deaths Raise Questions About CAR-T Safety

Novartis suspended eight trials of its experimental rap-cel CAR-T therapy in late August after three patients died from IEC-HS, a rare hyperinflammatory complication. Bristol Myers Squibb also paused enrolment in its autoimmune CAR-T studies, citing temporary inflammatory events among patients. On October 23, the company disclosed the death of a patient with multiple sclerosis participating in an early-stage trial. It said it had identified the cause of the safety issue and hoped to resume testing in 2027.

Novartis said it was working with investigators and external academic experts to understand the reasons behind the deaths. The company said it would release its findings once the analysis was complete and the results could contribute to patient care.

Researchers Seek More Information About Safety Risks

The deaths have raised concerns among researchers, including Georg Schett of the University of Erlangen-Nuremberg. His 2022 study, published in the New England Journal of Medicine, reported that five lupus patients achieved remission following CAR-T treatment. Subsequent studies showed lasting remission.

Schett said the lack of information about the Novartis cases has left doctors unable to assess the circumstances. He said details about the patients’ underlying diseases, how well their conditions were controlled and what emergency treatments they received would help researchers understand what happened.

He and CAR-T inventor Carl June of the University of Pennsylvania have attempted to examine the incidents in an article they submitted to the journal.

Schett suggested that Novartis’ shortened manufacturing process could be contributing to the inflammatory complications. The approach reduces cell production time from more than 10 days to fewer than two. He proposed that patients receiving cells in an immature form could experience a severe inflammatory response as the cells expand inside their bodies.

Meanwhile, Saira Sheikh of the University of North Carolina said high-grade inflammatory events observed in other programmes had been reversible with treatment.

Other CAR-T Programmes Continue Testing

Around 150 trials are investigating CAR-T therapies for lupus, alongside studies targeting conditions including myasthenia gravis, scleroderma, myositis, multiple sclerosis and stiff-person syndrome.

Dr. Cuoghi Edens of the University of Chicago Medicine said her hospital had experienced success with a CAR-T therapy from Cabaletta Bio, which uses a more traditional manufacturing process. The company has begun testing its treatment in patients as young as 12.

Edens said she recently discussed the informed-consent process with a 15-year-old patient. She also pointed to the potential long-term consequences of lupus when discussing how patients and families assess the risks associated with experimental treatments.

Why Lupus Patients Are Exploring CAR-T Therapy

Lupus is a chronic autoimmune disease in which the immune system mistakenly attacks healthy tissues and organs. It can affect the kidneys, heart, lungs, skin and joints, creating significant challenges for patients.

For people with severe Lupus, conventional treatments may not provide sufficient disease control. Some patients experience repeated flare-ups, organ damage and complications despite receiving multiple medications.

CAR-T therapy offers a different scientific approach. Instead of simply suppressing immune activity, researchers are investigating whether modified immune cells can eliminate harmful immune cells and help rebuild a healthier immune system.

Latest news

A new blood test reveals an early ovarian cancer risk

Early Detection of Ovarian Precancer via Blood Marker The level of CA125 is raised in the blood during ovarian cancer....

According to sources, the US FDA shelving commissioner’s voucher scheme for quick drug reviews

FDA Shelves Fast-Track Drug Voucher Program Former U.S. Food and Drug Administration Commissioner Marty Makary's fast-track drug review program, launched...

Top 10 Technologies Transforming Pharmaceutical Facility Design

Executive Summary Pharmaceutical facility design is evolving as manufacturers respond to increasingly complex production requirements, stricter regulatory expectations, supply chain...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you